Skip to main content

Table 1 The main characteristics of studies included in the meta-analysis

From: The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis

Author

Year

Type of study

Region

Breast cancer subtype

Number of patients ( high / low TMB)

Type of therapy

Outcome

Sample source

TMB detection method

TMB cutoff value

Median / average* TMB (Range)

Wen [31]

2022

Article

Multiple areas

HER2 + 

216

( 43 / 173)

Chemotherapy, Chemotherapy plus HER2 + targeted therapy

OS

tissue

NA

3.05 Mut/Mb

3.05 Mut/Mb*

Liao(a) [29]

2022

Article

China

breast cancer

OS:139

( 36 / 103) PFS:128

( 29 / 99)

Chemotherapy,

Endocrine therapy, Radiotherapy

OS,

PFS

blood

NGS (PredicineCARE)

4.3 Mut/Mb

24.8 Mut/Mb

( 0–324)

Liao(b) [29]

2022

Article

China

HER2 + 

39

( 13 / 26)

Chemotherapy,

Endocrine therapy, Radiotherapy

OS

blood

NGS

(PredicineCARE)

4.3 Mut/Mb

NA

Liao(c) [29]

2022

Article

China

TNBC

34

( 8 / 26)

Chemotherapy,

Endocrine therapy, Radiotherapy

OS

blood

NGS

(PredicineCARE)

4.3 Mut/Mb

NA

Makhlin [32]

2021

Conference abstratct

Multiple areas

breast cancer

188

( 13 / 175)

NA

OS

tissue

NA

3 mutations

2.2mutations*

( NA)

Gao [33]

2021

Article

Multiple areas

TNBC

101

( 49 / 52)

NA

OS

tissue

NA

1.26 Mut/Mb

1.26 Mut/Mb

( 0.05–28.03)

Anwar(a) [30]

2021

Article

China

HER2 + 

28

( 8 / 20)

HER2 + targeted therapy

OS,

PFS

blood

NGS(OncoMD/OncoMD-Plus)

5.0 Mut/Mb

3.0 Mut/Mb

(0–22)

Anwar(b) [30]

2021

Article

China

HER2 + 

with brain metastasis

8

( 6 / 2)

HER2 + targeted therapy

OS,

PFS

blood

NGS(OncoMD/OncoMD-Plus)

5.0 Mut/Mb

NA

Chen [21]

2020

Article

China

HER2 + 

28

( 8 / 20)

HER2 + targeted therapy

PFS

blood

NGS(OncoMD/OncoMD-Plus)

5.0 Mut/Mb

3.0 Mut/Mb

(0–22)

Emens(a) [12]

2020

Conference abstratct

Multiple areas

TNBC

579

( 144 / 435)

ICIs

OS,

PFS

tissue

NGS (FoundationOne)

7.02 Mut/Mb

4.39 Mut/Mb(0–46.51)

Emens(b) [12]

2020

Conference abstratct

Multiple areas

TNBC

(PD-L1-)

NA

ICIs

PFS

tissue

NGS (FoundationOne)

7.02 Mut/Mb

NA

Emens(c) [12]

2020

Conference abstratct

Multiple areas

TNBC

(PD-L1 +)

NA

ICIs

PFS

tissue

NGS (FoundationOne)

7.02 Mut/Mb

NA

Barroso-Sousa [17]

2020

Article

Multiple areas

TNBC

62

( 12 / 50)

ICIs, ICIs plus Chemotherapy/ Targeted therapy

OS,

PFS

tissue

NGS (OncoPanel)

10 Mut/Mb

6 Mut/Mb

( NA)

Li [34]

2020

Article

Multiple areas

breast cancer

44

(10% / 90%)

ICIs

OS

tissue /blood

NGS (MSK-IMPACT)

6.8 Muts/MB

NA

Samstein [22]

2020

Article

Multiple areas

breast cancer

45

( 12 / 33)

ICIs

OS

blood

NGS (MSK-IMPACT)

5.9 Muts/MB

3.94 Mut/Mb

(0–46.52)

Park [13]

2018

Article

Korea

HER2 + 

OS: 46

( 16 / 30)

PFS: 37

( 13 / 24)

Chemotherapy plus HER2 + Targeted therapy

OS,

PFS

tissue

WES

100 mutations

NA

  1. *represented the value was average value